Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

This study is testing whether a targeted therapy drug called lazertinib (with or without chemotherapy) given before surgery can shrink tumors and improve surgical outcomes in patients with early to mid-stage non-small cell lung cancer that has a specific genetic mutation (EGFR mutation). **You may be eligible if...** - You are 19 or older - You have non-squamous non-small cell lung cancer (Stages IB–IIIB) that is surgically removable - Your tumor has a confirmed EGFR mutation (specifically exon 19 deletion or L858R) - Your overall health is good enough to tolerate surgery and treatment **You may NOT be eligible if...** - Your tumor does not have an EGFR mutation - Your cancer is not surgically removable - You have significant heart, liver, or lung problems that would make surgery unsafe - You are pregnant Talk to your doctor to see if this trial is right for you.